Karpas 422

Manufactured by Leibniz Institute DSMZ

Sourced in Germany

Karpas-422 is a product offered by the Leibniz Institute DSMZ. It is a laboratory equipment used for biological research and analysis. The core function of Karpas-422 is to facilitate the study and examination of cellular samples.

Automatically generated - may contain errors

Lab products found in correlation

6 protocols using karpas 422

Comprehensive BL and DLBCL Cell Line Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

BL cell lines (Ramos, BL-41, Namalwa, Daudi, Jiyoye, Raji) and DLBCL cell lines (BJAB, SU-DHL-5, WSU-NHL, OCI-Ly1, WSU-DLCL2, Karpas-422, HT, OCI-Ly19, SU-DHL-4, and DoHH2) were purchased from DSMZ, Braunschweig, Germany. The culture conditions, analysis of cell line identity, and mycoplasma status were analysed as described in Supplementary Methods.

Gehringer F., Weissinger S.E., Möller P., Wirth T, & Ushmorov A. (2019). Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma. Leukemia, 34(3), 857-871.

+ Open protocol

+ Expand

Cell Line Generation and Cultivation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

DOHH2, SUDHL4 (FL), SUDHL6, SUDHL10, OCILY3, Karpas 422 and SUDHL5 (DLBCL) were obtained from DSMZ (Braunschweig, Germany). DOHH2, SUDHL4, OCILY3, Karpas 422 cells were routinely grown at 37°C at 5% CO₂ in RPMI 1640 supplemented with 10% fetal calf serum (FCS), ultra-glutamine, penicillin and streptomycin (100U/ml). SUDHL5, SUDHL6 and SUDHL10 cells were cultured with 20% FCS. Five LCLs were generated from peripheral blood mononuclear cells by infection with B95.8 virus. One LCL was used to compare in the 2-D experiments, the other four were used in the validation and functional studies. LCLs were routinely grown in RPMI 1640 with 10% FCS. For the production of LCLs from peripheral blood permission was granted by the Institutional Review board (medical ethical committee UMCG) and written informed consent was obtained.

Wu R., Nijland M., Rutgers B., Veenstra R., Langendonk M., van der Meeren L.E., Kluin P.M., Li G., Diepstra A., Chiu J.F., van den Berg A, & Visser L. (2016). Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas. PLoS ONE, 11(1), e0146624.

+ Open protocol

+ Expand

Characterization of DLBCL Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human DLBCL cell lines Karpas-422, SU-DHL-4, WSU-DLCL2, SU-DHL-10, SU-DHL-6, DB, DOHH-2, HT, and SU-DHL-8 were purchased from DSMZ. The TOLEDO cell line was purchased from ATCC. OCI-LY1 and OCI-LY3 were provided by the Louis M. Staudt lab (Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA); HBL-1 and OCI-LY10 were provided by the Michael Gold lab (Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada). Karpas-422, SU-DHL-4, SU-DHL-10, SU-DHL-8, SU-DHL-6, and DB were cultured in RPMI 1640 (Thermo Fisher Scientific) supplemented with 20% FBS (Thermo Fisher Scientific). WSU-DLCL2, DOHH-2, OCI-LY1, HT, HBL-1, and TOLEDO were cultured in RPMI 1640 supplemented with 10% FBS. OCI-LY1 and OCI-LY10 were cultured in IMDM supplemented with 10% and 20% FBS, respectively. All cell lines were confirmed to be negative for mycoplasma using Venor GeM Mycoplasma Detection Kit, PCR-based (MilliporeSigma, MP0025). All cell lines were authenticated by STR profiling (The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Canada, Supplemental Table 10). Mutations in EZH2 in the cell lines were evaluated using the COSMIC (https://cancer.sanger.ac.uk/cosmic) databases and in-house whole-genome or whole-exome sequencing data.

Takata K., Chong L.C., Ennishi D., Aoki T., Li M.Y., Thakur A., Healy S., Viganò E., Dao T., Kwon D., Duns G., Nielsen J.S., Ben-Neriah S., Tse E., Hung S.S., Boyle M., Mun S.S., Bourne C.M., Woolcock B., Telenius A., Kishida M., Rai S., Zhang A.W., Bashashati A., Saberi S., D’Antonio G., Nelson B.H., Shah S.P., Hoodless P.A., Melnick A.M., Gascoyne R.D., Connors J.M., Scheinberg D.A., Béguelin W., Scott D.W, & Steidl C. (2022). Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. The Journal of Clinical Investigation, 132(10), e145343.

+ Open protocol

+ Expand

Cell Line Maintenance for DLBCL Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human DLBCL cell lines DOHH-2 and Karpas422 were purchased from DSMZ and ATCC, respectively, and maintained in RPMI-1640 (Life Technologies) containing 10% or 20% FBS (Life Technologies), respectively. The mouse cell line A20 was provided by A. Beilhack (University of Würburg, Germany), and maintained in RPMI-1640 containing 10% FBS. NU-DUL-1 was provided by M. Dyer (University of Leichester, UK), and maintained in RPMI-1640 containing 10% FBS. The Jurkat cell line was provided by A. Weng (BC Cancer, Vancouver, Canada), and maintained in RPMI-1640 containing 10% FBS, 1% sodium pyruvate and 1% nonessential amino acids (all from Life Technologies). HEK293-T cells were purchased from Open Biosystems, and cultured in DMEM plus 10% FBS. For all studies, FBS was heat inactivated, by heating serum at 56 °C for 30 min before addition to medium. NSGmice were purchased from an in-house source (Animal Resource Centre, BC Cancer, Vancouver, BC). Balb/c mice were purchased from Envigo. All mouse studies were approved by the Institutional Animal Care Committee (IACC) at the University of British Columbia, in accordance with the Canadian Council on Animal Care Guidelines. This study was approved by the Research Ethics Board of the University of British Columbia and the BCCA, conducted in accordance with the Declaration of Helsinki. Details are available in the Supplementary Methods.

Ennishi D., Healy S., Bashashati A., Saberi S., Hother C., Mottok A., Chun Chan F., Chong L., Abraham L., Kridel R., Boyle M., Meissner B., Aoki T., Takata K., Woolcock B.W., Viganò E., Gold M., Molday L.L., Molday R.S., Telenius A., Li M.Y., Wretham N., Santos N.D., Wong M., Viller N.N., Uger R.A., Duns G., Baticados A., Madero A., Bristow B.N., Farinha P., Slack G.W., Ben-Neriah S., Lai D., Zhang A.W., Salehi S., Shulha H.P., Chiu D.S., Mostafavi S., Gerrie A.S., Huang D.W., Rushton C., Villa D., Sehn L.H., Savage K.J., Mungall A.J., Weng A.P., Bally M.B., Morin R.D., Cohen Freue G.V., Staudt L.M., Connors J.M., Marra M.A., Shah S.P., Gascoyne R.D., Scott D.W, & Steidl C. (2020). TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nature medicine, 26(4), 577-588.

+ Open protocol

+ Expand

Establishment and Characterization of DLBCL Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

RL (GCB-DLBCL) and U2932 (ABC-DLBCL) cell lines were obtained from American Type Culture Collection (Rockville, MD). Rituximab-resistant cell lines (RL 4RH and U2932 4RH) were created as described previously (Czuczman et al. 2008 (link)). Other cell lines representing ABC-DLBCL (TMD8, HBL-1) and GCB-DLBCL (SUDHL-4, SUDHL-6, SUDHL-10, OCI-LY2, OCI-LY19, BJAB, HT, DB, Karpas-422, NUDHL-1) were obtained from Leibniz Institute/German Collection of Microorganisms and Cell Cultures (DSMZ). All cell lines were maintained in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Norcross, GA), 5mM HEPES, 100U/mL penicillin and 100μg/mL streptomycin (Life Technologies, Grand Island, NY) at 37^oC and 5%CO₂.
Neoplastic B-cells were isolated from pre-treatment biopsy tissue (either lymph node or extranodal tumor tissue) obtained from patients with B-cell NHL or Hodgkin lymphoma (HL) receiving therapy at Roswell Park Comprehensive Cancer Center (RPCCC) as previously described (Brem et al. 2011 (link)).

Torka P., Mavis C., Kothari S., Belliotti S., Gu J., Sundaram S., Barth M, & Hernandez‐Ilizaliturri F.J. (2020). Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma. EJHaem, 1(1), 122-132.

+ Open protocol

+ Expand

Establishing Rituximab-Resistant DLBCL Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

RL (GCB‐DLBCL) and U2932 (ABC‐DLBCL) cell lines were obtained from American Type Culture Collection (Rockville, MD). Rituximab‐resistant cell lines (RL 4RH and U2932 4RH) were created as described previously [17 (link)]. Other cell lines representing ABC‐DLBCL (TMD8, HBL‐1) and GCB‐DLBCL (SUDHL‐4, SUDHL‐6, SUDHL‐10, OCI‐LY2, OCI‐LY19, BJAB, HT, DB, Karpas‐422, NUDHL‐1) were obtained from Leibniz Institute/German Collection of Microorganisms and Cell Cultures (DSMZ). All cell lines were maintained in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% heat‐inactivated fetal bovine serum (Atlanta Biologicals, Norcross, GA), 5 mM HEPES, 100 U/mL penicillin, and 100 µg/mL streptomycin (Life Technologies, Grand Island, NY) at 37°C and 5% CO₂.
Neoplastic B‐cells were isolated from pre‐treatment biopsy tissue (either lymph node or extranodal tumor tissue) obtained from patients with B‐cell NHL or Hodgkin lymphoma (HL) receiving therapy at Roswell Park Comprehensive Cancer Center (RPCCC) as previously described [18 (link)].

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!